Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alzheimer’s Plan Emphasizes Acceleration, Sets Timeline On Prevention, Cure

Executive Summary

Ambitious draft plan from the Obama administration includes public/private efforts to shorten drug development times and pick up the pace of clinical trials, including more efficient ways of identifying and enrolling participants.

You may also be interested in...

Alzheimer’s Research Can’t Use Prevention Funds, Harkin Tells NIH

Senator reiterates his support for Alzheimer’s research, but says the appropriations committee will not pay for it with money intended to support proven methods to prevent disease.

FDA Expanding Accelerated Approval Through Guidance, Collaboration

Disease communities will have to be engaged in developing endpoints needed to make accelerated approval happen for more drugs; FDA acknowledges that the pathway is “underutilized in many areas.”

Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts